BioSig Technologies Announces PURE-EP System Clinical Data

The first presentation was co-authored by Pedram Kazemian, M.D. et al., of Deborah Heart and Lung Center in Browns Mills, New Jersey, is titled, “Post-Ablation Bipolar Voltage By PURE EP(tm) As a Marker Of Transmural Lesion.”

The second abstract was co-authored by Jonathan Salas, B.S.; Pasquale Santangeli, M.D.; David Callans, M.D.; Francis E. Marchlinski, M.D.; Cory M. Tschabrunn, Ph.D. of University of Pennsylvania in Philadelphia, Pennsylvania, is titled, “Atrial Unipolar Electrogram Filtering to Better Delineate EGM Amplitude and Morphology During Radiofrequency Ablation.”
BioSig’s PURE EP System is designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals during complex ablation procedures.
The company completed enrollment for its second multi-center clinical trial in April 2021 and looks forward to sharing PURE EP’s most recent clinical data in-person at the Heart Rhythm 2021 convention on July 28-31, 2021.
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version